SCHEMBL481303

SCHEMBL481303

CC(C)[Si](OCc1cccc(Br)c1)(C(C)C)C(C)C

nearest known ligand 0.53

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.53
AGXT P21549 2/20 0.53
MAOB P27338 10/20 0.50
TAAR1 Q96RJ0 3/20 0.46
SIGMAR1 Q99720 1/20 0.42
MAOA P21397 2/20 0.41
HCAR2 Q8TDS4 1/20 0.41
PYCR1 P32322 1/20 0.41
PTGES O14684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1033057 0.83 IDO1 (0.50) IDO1AGXTMAOBTAAR1MAOA
SCHEMBL145704 0.79 MAOB (0.43) IDO1MAOBMAOA
SCHEMBL481295 0.78 IDO1 (0.47) IDO1MAOBTAAR1PYCR1
SCHEMBL1315107 0.77 TSHR (0.46) IDO1AGXTTAAR1SIGMAR1MAOA
SCHEMBL9207416 0.77 IDO1 (0.44) IDO1AGXTMAOBTAAR1SIGMAR1
SCHEMBL30350635 0.77 IDO1 (0.58) IDO1AGXTMAOBTAAR1MAOA
SCHEMBL13412791 0.77 IDO1 (0.58) IDO1AGXTMAOBTAAR1MAOA
SCHEMBL9197307 0.76 IDO1 (0.50) IDO1AGXTMAOBTAAR1MAOA
SCHEMBL3507204 0.76 TACR1 (0.38) HCAR2
SCHEMBL25219446 0.76 MAOA (0.48) MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441762-A1 Potentiators of Glutamate Receptors Eli Lilly and Company (US) 2012-04-18 EP disclosed
EP-1817301-B1 POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2012-02-01 EP disclosed
US-7816523-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-10-19 US disclosed
US-7803938-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-09-28 US disclosed
US-20090318481-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-20090318483-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-7625937-B2 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators MERCK & CO., INC. (US) 2009-12-01 US disclosed
US-7598423-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-10-06 US disclosed
US-20080139505-A1 Potentiators Of Glutamate Receptors ARRAY BIOPHARMA, INC. 2008-06-12 US disclosed
US-20080076795-A1 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators MERCK SHARP & DOHME CORP. 2008-03-27 US disclosed
US-7282591-B2 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators MERCK & CO., INC. (US) 2007-10-16 US disclosed
EP-1817301-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-15 EP disclosed
WO-2006057870-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139505-A1 Potentiators Of Glutamate Receptors GRM1, GRIN1, GRM2 IDO1 2210/4885AGXT 949/4885MAOB 1372/4885
US-20090318481-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 IDO1 3036/4885AGXT 1731/4885MAOB 1955/4885
US-20080076795-A1 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators NR3C1, NR3C2, GRK5 IDO1 1210/4885AGXT 4017/4885MAOB 4368/4885
US-20090318483-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 IDO1 3036/4885AGXT 1731/4885MAOB 1955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.